| Phase 19 trials |
|
Phase 1
|
NCT05698043 |
Jul → Sep 2023 |
hyperlipidemia, combined, 2 |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05552495 |
Sep → Nov 2022 |
hyperlipidemia, combined, 2 |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05245084 |
Mar → Jun 2022 |
hyperlipidemia, combined, 2 |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04987970 |
Sep → Nov 2021 |
— |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04694989 |
Feb → Apr 2021 |
hyperlipidemia, combined, 2 |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04673864 |
Jan → Mar 2021 |
— |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03920579 |
Apr → May 2019 |
hyperlipidemia, hypertensive disorder |
Chong Kun Dang Pharmaceutical |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT03726866 |
Aug 2018 → Jan 2019 |
hyperlipidemia, hypertensive disorder |
Chong Kun Dang Pharmaceutical |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT03609606 |
Aug → Sep 2018 |
hyperlipidemia, hypertensive disorder |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT04388215 |
Oct 2019 → Apr 2021 |
essential hypertension, hyperlipidemia |
Chong Kun Dang Pharmaceutical |
Unknown
|
No outcome recorded
|
|
Phase 3
|
NCT04312698 |
Aug 2019 → Jun 2021 |
hyperlipidemia |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|